Vellore Typhoid Vaccine Impact Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

72,500

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Typhoid Fever
Interventions
BIOLOGICAL

Typhoid conjugate Vaccine

TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.

Trial Locations (1)

632002

RECRUITING

Christian Medical College Vellore, Vellore

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

University College, London

OTHER

collaborator

Imperial College London

OTHER

lead

Christian Medical College, Vellore, India

OTHER